Overview

Therapeutic Effect of Sildenafil in Patients With Coronary Vasospasm

Status:
Withdrawn
Trial end date:
2009-12-31
Target enrollment:
Participant gender:
Summary
This will be a prospective, phase IIIb, double-blind and randomized trial testing the effect of single dose sildenafil application in patients with coronary vasospasm compared to placebo application. The target variable to be tested is the degree of coronary vasoconstriction in response to intracoronary ACh application (in addition to clinical chest pain) which will be imaged by coronary angiography and measured using quantitative coronary angiography software. Main objective: Has sildenafil the potency to inhibit the induction of coronary vasospasm by intracoronary ACh-application in patients with proven coronary artery spasm? Secondary objective: Which degree of coronary vasospasm inhibition can be achieved with sildenafil?
Phase:
Phase 3
Details
Lead Sponsor:
Udo Sechtem
Treatments:
Sildenafil Citrate